Teva Pharmaceutical Industries Ltd. has posted impressive first-quarter results for 2026, featuring a revenue increase to approximately $4.0 billion and a 72% surge in net income to $369 million, signaling strong financial health. The company's positive momentum was further supported by Blackstone's $400 million investment and a credit rating upgrade to BB+ from S&P Global, which has collectively propelled Teva's stock by over 11%. While Teva maintains a cautious revenue outlook for the year at $16.4 billion to $16.8 billion, the company is also focused on sustainability efforts and awaiting FDA approvals for key products.
“Teva Pharmaceutical Industries · could see · further upside · as its valuation re-rates, supported”
“Teva Pharmaceutical Industries · released · first quarter 2026 results · higher sales, net income and earnings per share compared with a year earlier”
“Teva Pharmaceutical Industries TEVA · reported · first-quarter 2026 adjusted earnings · 53 cents per share”
“Teva Pharmaceutical Industries TEVA · recorded · revenues for the first quarter · $3.98 billion”
“Blackstone · made a commitment to · Teva Pharmaceutical Industries Ltd. · $400 million”
“Teva and its partner, Sanofi · are evaluating · duvakitug · Phase 3 clinical studies”
“Teva · is recognized as · a leading biopharmaceutical innovator · true”
“Teva · is awaiting FDA approval for · Olanzapine long-acting injectable · true”
“S&P Global · upgraded Teva's credit rating to · BB+ · from BB”
“Of the 13 analysts surveyed by S&P Global · rated Teva stock as · "buy" or "strong buy" · 12”
“The Motley Fool Stock Advisor · did not include Teva Pharmaceutical Industries in · the 10 best stocks for investors to buy now · true”
“Teva · exceeded · sustainability-linked bond targets · all”
